NCT03337022View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

April 26, 2019

Study Completion Date

April 26, 2019

Conditions
Psoriasis
Interventions
DRUG

CC-90006

CC-90006

OTHER

Placebo

Placebo

Trial Locations (4)

16635

Altoona Center for Clinical Research, Duncansville

92801

Anaheim Clinical Trials, LLC, Anaheim

07410

TKL Research, Fair Lawn

H2K 4L5

Innovaderm Research, Montreal

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY